Satyam Devang Patel

Mr. Satyam Devang Patel

Department of Pharmacology, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2023 in Cells
Verified
Journal Article
Open access
PDF file
NMNaresh Kumar Manda
Naresh Kumar Manda
Upendar Rao GollaUpendar Rao Golla
Upendar Rao Golla
KSKishore Sesham
Kishore Sesham
PDParth Hemantkumar Desai
Parth Hemantkumar Desai
SJShrushti Joshi
Shrushti Joshi
Namita RokanaNamita Rokana
Namita Rokana
The organization of eukaryotic genome in the nucleus, a double-membraned organelle separated from the cytoplasm, is highly complex and dynamic. The functional architecture of the nucleus is confined by the layers of internal and cytoplasmic elements, including chromatin organization, nuclear envelope associated proteome and transport, nuclear–cytoskeletal contacts, and the mechano-regulatory signaling cascades. The size and morphology of the nucleus could impose a significant impact on nuclear mechanics, chromatin organization, gene expression, cell functionality and disease development. The maintenance of nuclear organization during genetic or physical perturbation is crucial for the viability and lifespan of the cell. Abnormal nuclear envelope morphologies, such as invagination and blebbing, have functional implications in several human disorders, including cancer, accelerated aging, thyroid disorders, and different types of neuro-muscular diseases. Despite the evident interplay between nuclear structure and nuclear function, our knowledge about the underlying molecular mechanisms for regulation of nuclear morphology and cell functionality during health and illness is rather poor. This review highlights the essential nuclear, cellular, and extracellular components that govern the organization of nuclei and functional consequences associated with nuclear morphometric aberrations. Finally, we discuss the recent developments with diagnostic and therapeutic implications targeting nuclear morphology in health and disease.

12 October 2024 in Cancers
Verified
Journal Article
Open access
PDF file
Upendar Rao GollaUpendar Rao Golla
Upendar Rao Golla
Satyam Devang PatelSatyam Devang Patel
Satyam Devang Patel
NSNyah Shah
Nyah Shah
STStella Talamo
Stella Talamo
RBRiya Bhalodia
Riya Bhalodia
ASArati Sharma
Arati Sharma
Drug repurposing is a strategy to discover new therapeutic uses for existing drugs, which have well-established toxicity profiles and are often more affordable. This approach has gained significant attention in recent years due to the high costs and low success rates associated with traditional drug development. Drug repositioning offers a more time- and cost-effective path for identifying new treatments. Several FDA-approved non-chemotherapy drugs have been investigated for their anticancer potential. Among these, anthelmintic benzimidazoles (such as albendazole, mebendazole, and flubendazole) have garnered interest due to their effects on microtubules and oncogenic signaling pathways. Blood cancers, which frequently develop resistance and have high mortality rates, present a critical need for effective therapies. This review highlights the recent advances in repurposing benzimidazoles for blood malignancies. These compounds induce cell cycle arrest, differentiation, tubulin depolymerization, loss of heterozygosity, proteasomal degradation, and inhibit oncogenic signaling to exert their anticancer effects. We also discuss current limitations and strategies to overcome them, emphasizing the potential of combining benzimidazoles with standard therapies for improved treatment of hematological cancers.

29 February 2024 in Blood Advances
Verified
Journal Article
Open access
PDF file
BPBishal Paudel
Bishal Paudel
STSu-Fern Tan
Su-Fern Tan
TFTodd E. Fox
Todd E. Fox
JUJohnson Ung
Johnson Ung
Upendar Rao GollaUpendar Rao Golla
Upendar Rao Golla
TLThomas P. Loughran
Thomas P. Loughran

4 April 2023 in Cancer Research
Verified
Journal Article
Closed access
UGUpendarrao Golla
Upendarrao Golla
Satyam Devang PatelSatyam Devang Patel
Satyam Devang Patel
DTDiwakar B. Tukaramrao
Diwakar B. Tukaramrao
JHJeremy Hengst
Jeremy Hengst
JRJuliana Restrepo
Juliana Restrepo
ASArati Sharma
Arati Sharma
Acute Myeloid Leukemia (AML) is a rare but catastrophic hematological cancer with a poor prognosis, high mortality, and relapse rates. Several new agents targeting specific genes or cell survival pathways have been recently approved by the FDA. AML treatment with single agents often results in resistance; therefore, combination therapies may provide more durable and effective responses. Rho kinases (ROCK1/2) are aberrantly expressed in AML patient cells, and ROCK1 has emerged lately as a potential therapeutic target for AML treatment. Previously, our group developed a new ROCK inhibitor DJ4 as an effective inducer of AML cell death. Our initial screening of DJ4 with AML standard therapy (cytarabine, daunorubicin, azacytidine, venetoclax) showed promising synergy between DJ4 and the BCL2 (B-cell lymphoma-2) inhibitor venetoclax (VEN). Enrichment of ROCK pathway in recent CRISPR drop-out screening after VEN treatment in MOLM-13 cells further validates the synergistic cooperation between ROCK and BCL2 pathways. Though VEN is widely used in hematological malignancies, its clinical efficacy is limited due to the development of resistance. Thus, we sought to investigate the novel strategy of combining VEN with ROCK inhibitors (ROCKi) for AML treatment. The combination of VEN with ROCKi (Fasudil, Y-27632, GSK269962A, DJ4) exhibited synergetic cytotoxicity in naïve (MOLM-13, MV4-11) and VEN-resistant (MV4-11/VENR, HL-60, OCI-AML3, U937) human AML cell lines. Flow cytometric analysis of Annexin V and cellular ROS levels in MV4-11 (naïve and VENR) cells upon co-treatment with sub-lethal doses of VEN and ROCKi demonstrated a significant (p<0.05) increase in the apoptosis and oxidative stress compared to single agents. Treatment of MV4-11 cells with VEN+ROCKi enhanced the activity of several caspases in the MultiCaspase assay. Furthermore, the colony-forming ability of AML cell lines and primary AML patient cells was significantly reduced with the combination treatment, while single agents exhibited minimal effects. MV4-11 (naïve and VENR) cells displayed alterations in the levels of critical apoptosis regulators (Bcl2, Bax, Mcl1, cleaved caspase-3) upon co-treatment in immunoblotting analysis. Additionally, MV4-11-Luc xenograft mice exhibited a significant reduction in the average leukemic burden after combination therapy relative to single agents (p<0.05). Altogether, our in vitro and in vivo findings established a synergetic interaction between VEN and ROCKi to effectively inhibit AML cell progression and overcome the VEN resistance (inherent or acquired). These results indicate that therapy co-targeting BCL2 and ROCK pathways exerted antileukemic activity by inducing apoptosis and may be particularly effective for AML treatment. Further studies are ongoing to explore the precise molecular mechanism of action of the VEN+ROCKi combination and its efficacy in pre-clinical animal models. Citation Format: Upendarrao Golla, Satyam Patel, Diwakar B. Tukaramrao, Jeremy Hengst, Juliana Restrepo, Shantu Amin, Dhimant Desai, Sinisa Dovat, David Claxton, Arati Sharma. ROCK inhibitors synergize with the BCL2 inhibitor venetoclax for treatment of AML [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2677.

4 April 2023 in Cancer Research
Verified
Journal Article
Closed access
Satyam Devang PatelSatyam Devang Patel
Satyam Devang Patel
UGUpendarrao Golla
Upendarrao Golla
ASArati Sharma
Arati Sharma
DCDavid Claxton
David Claxton
Studies with acute myeloid leukemia (AML) cell lines have limited potential as they tend to acquire mutations, thus, do not represent typical leukemias found in patients. Ex vivo culturing of primary human AML patient cells is therefore of interest; however, the long-term culture of these cells has been limited by rapid differentiation and loss of clonogenicity. Previously, different growth factors and stromal cells were implicated in the short-term culturing of primary cells. Thus, we aimed to evaluate culture conditions using a cytokine cocktail, allowing long-term expansion and phenotypic maintenance of primary AML cells in vitro. Different culture conditions were constituted by combination of cytokines (SCF, FLT-3L, TPO, IL-6, IL-3, GCSF, GM-CSF) and small molecules (SR1, UM729) in serum-free StemSpan SFEM media. The ability of different growth mediums to support the expansion and clonogenicity of 6 primary AML cells (collected from blood/bone marrow) over two weeks was assessed using cell counts and colony formation assays. Additionally, cell surface markers (hCD34, hCD45, hCD123, hCD117) were assessed by flow cytometry during the culture period. All tested cultured conditions exhibited successful cell proliferation (4-6-fold expansion) and survival of primary AML cells over two weeks of culture. In addition, the growth media successfully supported 3.5-fold CD34+ stem cell expansion. Growth mediums with early-acting cytokines (SCF, FLT-3L, TPO, and IL-6) and small molecules resulted in phenotypic maintenance of cell surface markers (CD34, CD123) and secondary clonogenicity of primary AML cells over the culture period. The addition of late-acting cytokines (IL-3, GCSF, and GM-CSF) showed a higher growth rate but negatively affected the cell surface markers and clonogenicity. Secondary colony counts (day-9 culture) showed a significant positive correlation with CD34 expression levels. Thus, CD34 levels could serve as a potential surrogate marker for the clonogenicity of primary AML cells. Furthermore, we tested the engraftment ability of two primary AML cells grown in 3 of our promising culture conditions (Day 4, Day 8) in xenograft mice. Flow cytometry analysis on peripheral blood and tissues (spleen and bone marrow) from xenograft mice showed successful engraftment of primary cells cultured for 8 days. On an application note, the optimal condition from our results was used to study the effects of ceramide nanoliposomes (CNL) in AML patient cells. Interestingly, the AML patient cells treated for two weeks with IC15 and IC30 doses of CNL led to cell cycle arrest, reduced CD34 expression, and clonogenicity relative to control cells. The CNL findings from primary cells are different from that of cell lines cultured under the same conditions. Thus, our optimal growth conditions may facilitate researchers to understand AML biology and study various therapeutics under development using primary AML cells. Citation Format: Satyam Patel, Upendarrao Golla, Arati Sharma, David Claxton. Ex vivo culturing of primary AML cells facilitates the study of developmental therapeutics [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5798.